Abstract: Background: The presented study evaluated the suppositional changes in the airway expression of Nav1.7 and Nav1.8 and their role in the airway defense mechanisms in healthy animals and in an experimental asthma model. Methods: The effects of the blockers inhalation on the reactivity of guinea pig airways, number of citric-acid-induced coughs and ciliary beating frequency (CBF) were tested in vivo. Chronic inflammation simulating asthma was induced by repetitive exposure to ovalbumin. The expression of Nav1.7 and Nav1.8 was examined by ELISA. Results: The Nav 1.8 blocker showed complex antitussive and bronchodilatory effects and significantly regulated the CBF in healthy and sensitized animals. The Nav1.7 blockers significantly inhibited coughing and participated in CBF control in the ovalbumin-sensitized animals. The increased expression of the respective ion channels in the sensitized animals corresponded to changes in CBF regulation. The therapeutic potency of the Nav1.8 blocker was evidenced in combinations with classic bronchodilators. Conclusion: The allergic-inflammation-upregulated expression of Nav1.7 and Nav1.8 channels and corresponding effects of blocker inhalation on airway defense mechanisms, along with the Nav1.8 blocker’s compatibility with classic antiasthmatic drugs, bring novel possibilities for the treatment of various respiratory diseases. However, the influence of the Nav1.8 blocker on CBF requires further investigation.

Keywords: cough; bronchial hyperreactivity; ciliary beating frequency; asthma therapy; Nav1.8 channels

1. Introduction

Respiratory tract receptors and defensive reflexes, such as sneezing and coughing, have been extensively studied. The physiological roles of these receptors in modifying the respiratory and cardiovascular systems are of great interest, as is their potential importance in respiratory diseases [1]. The airways and lungs are innervated by heterogeneous populations of vagally derived sensory neurons originated from nodose or jugular ganglia, whose differences in functional, neurochemical, neuroanatomical and molecular expression characteristics have been clearly demonstrated regarding the regulation of respiratory reflexes in guinea pigs [2–5].

The initiation of airway defense reflexes is driven by the activation of afferent nerve endings through various receptors and ion channels. The activation of voltage-gated sodium channels (Navs) plays a key role in action potential (AP) generation and conduction in excitable cells, and their mutations or damage are responsible for the pathogenesis of various diseases [6]. There are nine distinct pore-forming alpha subunits of Navs that come from nine different genes. These channels are referred to as Nav1.1–Nav1.9. With the exception of Nav1.4, which is expressed in striated muscle, and Nav1.5, which is expressed...
in cardiac myocytes, all the Na\textsubscript{V}1s are expressed in neurons [7]. Studies in guinea pigs have shown that the vagal neurons innervating the respiratory tract express the Na\textsubscript{V}1.7, Na\textsubscript{V}1.8 and Na\textsubscript{V}1.9 isoforms [6,8].

Na\textsubscript{V}s are classified according to their sensitivity to tetrodotoxin (TTX) [9]. TTX is a blocker that preferentially blocks Na\textsubscript{V}1.1–1.4, Na\textsubscript{V}1.6 and Na\textsubscript{V}1.7 (TTX-sensitive channels) with low nanomolar potency as well as short-lasting effects and is approximately 100–1000-fold less potent in blocking Na\textsubscript{V}1.5, Na\textsubscript{V}1.8 and Na\textsubscript{V}1.9 (TTX-resistant channels) [6].

Na\textsubscript{V}1.7 is highly involved in the generation of action potentials in various types of excitable cells. The knockdown of Na\textsubscript{V}1.7 expression in the vagal sensory ganglia of guinea pigs abolished AP conduction and significantly suppressed the coughing induced by citric acid (AC). Na\textsubscript{V}1.7 is also highly expressed on unmyelinated C-fibers that also contain the neuropeptide substance-P and mediate bronchoconstriction. Furthermore, Rice et al. [10] and Jo et al. [11] demonstrated that the sodium channel Na\textsubscript{V}1.7 is present extraneuronally, e.g., within skin vascular myocytes and the endothelium of arterioles [10] or on cultured human smooth muscle cells [12].

Extensive evidence indicates that coughing caused by airway inflammation is mediated by the capsaicin-sensitive vagal afferent C-fibers, which, in the guinea pig, are the C-fibers originating from vagal jugular ganglia [13]. Na\textsubscript{V}1.8 is expressed on airway sensory C-fibers and A\textdelta-fiber neurons, and PGE2 increases their conductivity, spreading excitement and total irritability. Na\textsubscript{V}1.8 is a TTX-resistant ion channel that is significantly different from other neuronal TTX-resistant Na\textsubscript{V}s in its fast voltage activation and inactivation dependence [12]. This allows Na\textsubscript{V}1.8 to participate in the spreading of the AP during the period of permanent depolarization [14]. One of Na\textsubscript{V}1.8’s features is the fact that its usually high threshold for activation is significantly reduced after the exposure of sensory neurons to inflammatory mediators.

This different distribution paves the way for developing selective Na\textsubscript{V} blockers with therapeutic indexes much greater than can be obtained with nonselective local anesthetics [15]. Furthermore, the expression of Na\textsubscript{V} can be influenced by inflammatory mediators, as reported by Strickland et al. [16], which showed changes in Na\textsubscript{V}1.7, Na\textsubscript{V}1.8 and Na\textsubscript{V}1.9 expression in a rat model of Freund’s complete adjuvant (FCA)-induced chronic inflammatory joint pain. The alteration of Na\textsubscript{V}1.7, Na\textsubscript{V}1.8 or Na\textsubscript{V}1.9 expression leads to distinct changes in sensitivity in either inflammatory or neuropathic pain models [17].

The currently available antitussive drugs often have only limited efficacy in inhibiting excessive coughing in acute and chronic inflammatory respiratory diseases. Postganglionic parasympathetic nerves are responsible for reflex parasympathetic bronchospasm and mucus secretion. The mucus secretion may contribute to pathological coughing in some cases; likewise, cholinergic bronchoconstriction may increase cough sensitivity in those who suffer from hypersensitive cough syndromes [7]. Little information is available regarding their role (if any) in airway smooth muscle [18].

The specific expression, function and increasing evidence of the upregulation of the previously mentioned subtypes Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 by several mediators of allergic inflammation led to the assumption that selective blockers of these subtypes may represent a novel therapeutic strategy for diseases and symptoms associated with neuronal hyperexcitability in the respiratory tract. Except from their ability to inhibit coughing, these potential drugs can exhibit bronchodilatory activity. The object of many discussions is their cilio-modulatory activity, but this has not been confirmed yet.

The goal of the current study was to generate new knowledge about the pharmacodynamic effects of the Na\textsubscript{V} blockers in the respiratory tract. Their influence on the parameters of airway defense mechanisms after single-dose administration were examined under physiological conditions and during the inflammation of the airways. In our experimental conditions, we tested their ability to relieve coughing, decrease specific airway resistance (sRaw) (airway reactivity in in vivo conditions) and influence the ciliary beating frequency (CBF), one of the main parameters determining the efficiency of mucociliary clearance. Given the fact that several studies confirmed Na\textsubscript{V} upregulation during inflammatory con-
ditions, we compared the changes in the expression of various subtypes of Na\textsubscript{V} between healthy and sensitized groups of animals. One of the goals of the current study was to determine the most effective substance regarding the previously mentioned parameters and test its efficacy against that of clinically used antiasthmatics.

2. Materials and Methods

Adult male TRIK strain guinea pigs weighing 150–350 g (obtained from The Department of Experimental Pharmacology, Slovak Academy of Sciences, Dobra Voda, Slovakia) were used in the present study. All the protocols described in the study were approved by the local Ethic Committee (IRB00005636, decision No. EK 40/2018) and followed the aims and objectives of the ARRIVE guidelines. The investigation followed the Guide for the Care and Use of Laboratory Animals: Eighth Edition (2010) published by the US Committee for the Update of the Guide for the Care and Use of Laboratory Animals; the National Research Council; the EU-adopted Directive 2010/63/EU of the European Parliament and of the council on the protection of animals used for experimental and other scientific purposes; and Slovak law regulating animal experiments. To ensure the stability of the laboratory conditions (ambient temperature of 21–24 °C and relative humidity of 55 ± 10%) during the performance testing, an LG multi-type air-conditioner (LG Neo plasma, Slovakia) was used.

The research was complied with the commonly accepted ‘3Rs’. A total of 105 animals were used in the presented study. The animals were divided into 15 groups, each consisting of 7 animals (Table 1). Experimental airway inflammation was induced in 13 groups. The groups were divided into control groups—2 negative and 2 positive—and 11 experimental groups: 9 groups used for testing several concentrations of the investigated substances and 2 groups used to prove the effects of Na\textsubscript{V}1.8 blocker combinations with clinically used bronchodilatory antiasthmatics. The negative groups (sensitized OVA+ and unsensitized OVA−) received isotonic saline (0.9% NaCl, 5 min inhalation), and the positive control groups, salbutamol (4×10\textsuperscript{-3} mol/L, 5 min inhalation) or codeine phosphate (10 mg/kg; per os). ProTx III (10\textsuperscript{-8}, 10\textsuperscript{-7} or 10\textsuperscript{-6} mol/L and 5 min inhalation), huwentoxin IV (10\textsuperscript{-9}, 10\textsuperscript{-8} or 10\textsuperscript{-7} mol/L and 5 min inhalation), A803467 (10\textsuperscript{-8}, 10\textsuperscript{-7} or 10\textsuperscript{-6} mol/L and 5 min inhalation) were administered to 9 experimental groups. Two groups underwent treatment with a combination of A803467 at 10\textsuperscript{-8} mol/L with salbutamol at 4.10\textsuperscript{-3} mols/L or A803467 at 10\textsuperscript{-8} mol/L with ipratropium at 10\textsuperscript{-3} mol/L.

Tetrodotoxin (TTX) served for comparative purposes only in in vitro tests. All the chemicals used for the in vitro experiments were also administered directly on biological samples. For CBF testing in in vitro conditions, the same concentrations used for the inhalations were used. TTX was applied at concentrations of 10\textsuperscript{-9}–10\textsuperscript{-7} mol/L.

ProTx III is a potent Na\textsubscript{V}1.7 blocker (IC50 = 2.5 nM). It also inhibits Na\textsubscript{V}1.2, Na\textsubscript{V}1.3 and Na\textsubscript{V}1.6 in the nanomolar range. Huwentoxin IV preferentially inhibits neuronal Na\textsubscript{V}1.7, 1.2 and 1.3 (the IC50 values are 26, 150 and 338 nM, respectively), compared to the muscle subtypes Na\textsubscript{V}1.4 and 1.5 (IC50 ≥ 10 μM). The small molecule A803467 is a selective blocker of Na\textsubscript{V}1.8 channels (the IC50 value is 8 nM). A-803467 is over 100-fold more potent against Na\textsubscript{V}1.8 than human Na\textsubscript{V}1.2, 1.3, 1.5 and 1.7. For experimental purposes, the IC50s of the tested drugs were used. For the dose-dependence test, 1-fold higher and 1-fold lower concentrations were used.
Table 1. Design of the study.

| Group                  | The Name in the Graphs | Description of the Treatment                                      | Number of Animals in the Group |
|------------------------|------------------------|------------------------------------------------------------------|--------------------------------|
| OVA− saline            | OVA−                  | 5 min inhalation of 0.9% NaCl                                     | 7                             |
| OVA+ saline            | OVA+                  | 5 min inhalation of 0.9% NaCl after OVA                          | 7                             |
| Codeine                | codeine               | per oral administration, dose 10 mg/kg before and after OVA      | 7                             |
| Salbutamol             | salbutamol            | 5 min inhalation of 4.10^{-3} mol/L before and after OVA         | 7                             |
| A803467 10^{-8}        | A8                    | 5 min inhalation of 10^{-8} mol/L before and after OVA           | 7                             |
| A803467 10^{-7}        | A7                    | 5 min inhalation of 10^{-7} mol/L before and after OVA           | 7                             |
| A803467 10^{-6}        | A6                    | 5 min inhalation of 10^{-6} mol/L before and after OVA           | 7                             |
| ProTx III 10^{-8}      | P8                    | 5 min inhalation of 10^{-8} mol/L before and after OVA           | 7                             |
| ProTx III 10^{-7}      | P7                    | 5 min inhalation of 10^{-7} mol/L before and after OVA           | 7                             |
| ProTx III 10^{-6}      | P6                    | 5 min inhalation of 10^{-6} mol/L before and after OVA           | 7                             |
| Huwentoxin IV 10^{-9}  | H9                    | 5 min inhalation of 10^{-9} mol/L before and after OVA           | 7                             |
| Huwentoxin IV 10^{-8}  | H8                    | 5 min inhalation of 10^{-8} mol/L before and after OVA           | 7                             |
| Huwentoxin IV 10^{-7}  | H7                    | 5 min inhalation of 10^{-7} mol/L before and after OVA           | 7                             |
| A803467 10^{-8} + salbutamol | A8 + SAL            | 5 min inhalation of 10^{-8} A8 and 4.10^{-3} mol/L SAL after OVA | 7                             |
| A803467 10^{-8} + ipratropium | A8 + IPR            | 5 min inhalation of 10^{-8} A8 and 10^{-5} mol/L IPR after OVA   | 7                             |

The total number of animals 105

2.1. Chemicals

Salbutamol, ovalbumin from chicken egg white, histamine and DMSO solution were purchased from Sigma Aldrich (St. Louis, MO, USA). ProTx III, A803467, huwentoxin IV and TTX were obtained from TOCRIS (Bristol, UK). All the other chemicals used were purchased as listed: codeine phosphate (Slovakofarma Hlohovec, Slovakia); sodium chloride solution and methacholine (ApliChem, Darmstadt, Germany); RPMI 1640 medium (Invitrogen/Gibco, USA); aluminum hydroxide (CentralChem, Bratislava, Slovakia); and citric acid (AC) (ACROSorganics, Bratislava, Slovakia). According to the manufacturers’ instructions, the chemicals were dissolved in water for injection (salbutamol, ProTx III, huwentoxin IV and codeine), saline (ovalbumin, methacholine, AC, aluminum hydroxide and histamine), 10% DMSO (A803467) and acidic buffer (TTX).

2.2. Model of Experimentally Induced Airway Inflammation

An experimental model of allergic airway inflammation was induced by the 21-day administration of an allergen—ovalbumin (OVA)—to the adult male guinea pig strain TRIK. OVA, adsorbed on aluminum hydroxide (Al(OH)₃), was applied in a repetitive parenteral manner at the same dose (5 mg of OVA and 100 mg of Al(OH)₃—1st day i.p. and s.c., 4th day i.p. and 9th day s.c. The allergen was also administered by inhalation on the 12th, 15th, 18th and 20th days using a double-chamber bodyplethysmograph box for small animals (HSE type 855, Hugo Sachs Elektronik, Germany). All tests with the sensitized animals were performed 24 h after the last allergen administration.

2.3. Cough Reflex Assessment

The cough reflex was evoked by the inhalation of 0.3 M AC. An AC aerosol created by a nebulizer (PARI jet nebulizer, Paul Ritzau, Pari-Werk GmbH, Germany; output, 5 L·s⁻¹; particle mass median diameter, 1.2 µm) was delivered into a nasal chamber during a 3-min interval. Two trained observers counted the number of cough efforts according to the presence of typical movement, cough sounds and airflow curve changes.
The cough response was measured prior to the administration of any agent (baseline measurement, N value in graphs) and then 60 and 240 min after its application according to ERS guidelines [19].

2.4. Airway Smooth Muscle Reactivity In Vivo

The specific airway resistance (sRaw) was expressed as the airway reactivity in in vivo conditions. Awake guinea pigs were placed into a double-chamber bodyplethysmograph box for small animals (Hugo Sachs Elektronik, type 855) composed of separate nasal and body chambers. The sRaw values were calculated according to Pennock [20]. The airway resistance was recorded for 1 min immediately after histamine (10$^{-6}$ mols/L) and methacholine (10$^{-6}$ mols/L) inhalation before (N in graphs) and 60 and 240 min after the single administration of the substances. There was also a 1 min time interval between each bronchoconstrictor agent when the fresh air was blown into the nasal chamber.

2.5. Ciliary Beating Frequency

A PeCon Temp Controller 2000-2 (PeCon GmbH, Erbach, Germany) was utilized for the control and maintenance of the nutritive medium for the cilia temperature (RPMI 1640 Medium) and microscopic glass slides (37–38 degrees C). A sample of ciliary epithelium was obtained from the trachea using the brushing method in experimental in vitro conditions from negative control groups (OVA−, OVA+). A cytology brush (2.5-mm diameter) was placed in saline before brushing and then inserted directly into the trachea, rotated gently to collect ciliated cells and moved back. The cilia were suspended in 1 mL of RPMI 1640 Medium and used to make a microscopic preparation. The solution of tested and control drugs was applied directly on ciliary cells collected from trachea. An inverted phase contrast microscope (Zeiss Axio Vert. A1; Carl Zeiss AG, Göttingen, Germany) was used to examine the biological specimens. Impaired ciliated cells were excluded from this experiment. Over 15 min, with time series analysis, sequential 10-s video files were recorded at 1-min intervals using a digital high-speed video camera (Basler A504kc; Basler AG, Germany) at a frame rate ranging from 256 to 512 fps (frames per second). The video records were analyzed by virtual instrumentation using the Ciliary Analysis software (LabVIEW™) to generate a ciliary region of interest (ROI). This measurement method is based on a frequency analysis of intensity variance curve with the implementation of a fast Fourier transform algorithm [13]. Potential artefacts were filtered by the comparison of the ROI with the relevant video recording. The CBF was selected as the kinematic parameter for describing ciliary movement in the airways.

2.6. Enzyme-Linked Immunosorbent Assay (ELISA)

Homogenates from the bronchus and whole lung tissue were prepared by sonication (2 min) with a power output of 700 W (homogenizer, Stuart SHM2, ECOMED, Žilina) according to the manufacturer’s instructions. For analysis, the supernatant was collected into sterile tubes to determine the expression of Nav1.7 (after two freeze–thaw cycles to further break the cell membranes) and Nav1.8 (immediately after homogenization). The expression of the Nav1.7 and Nav1.8 isoforms was determined in lung and bronchial homogenates using a commercial ELISA kit for Guinea Pig Nav1.7, ELISA kit #MBS745877 (MyBioSource, USA), and Sodium Channel Protein Type 10 Subunit Alpha (SCN10A), ELISA Kit #MBS9349047 (MyBioSource, USA). The absorbance at 450 nm was measured using the Varioskan® Flash version 2.4.5.

2.7. Statistical Analysis

All the obtained data are shown as means ± the standard error of the mean (S.E.M.). For their statistical analysis, t-tests and ANOVA with Bonferroni post-hoc tests were used, as appropriate. The results with $p < 0.05$ and lower were considered statistically significant.
3. Results

The aim was to verify the role of the voltage-gated sodium channels in the respiratory tract and also the differences between physiological and pathological situations in the airways. The changes of all tested parameters between OVA− and OVA+ groups are obvious. The recorded increase in sRaw values between OVA− and OVA+ group is almost 3 times higher and the number of coughs efforts grew almost by 50%. Substances capable of blocking Nav1.7 (huwentoxin IV and ProTx III) and Nav1.8 (A803467) were applied to animals by single-dose inhalation, and all the parameters in vivo were measured before and 60 and 240 min after drug inhalation. Their effects on the AC-induced cough reflex and ability to influence the sRaw elicited by the administration of bronchoconstrictors (histamine and methacholine) were monitored. The ability to reduce the CBF after the local application of the tested substances was monitored under in vitro conditions.

3.1. Results

3.1.1. Effect on Cough Reflex

Under physiological conditions, ProTx III (the selective Nav1.7 blocker) reduced the number of coughs at all tested doses (Figure 1A). After the development of airway inflammation, ProTx III decreased the number of coughs with statistical significance only when the measurement was performed 60 min after the inhalation of the agent at a concentration of 10−6 mols/L (Figure 1D). In healthy animals, huwentoxin IV, with a preferential effect on Nav1.7, significantly reduced the number of cough efforts, especially for the middle tested concentration, at which the cough suppression lasted longer (Figure 1B), and also in OVA-sensitized guinea pigs, where the suppressive effect was limited to the measurement 60 min after the drug inhalation (Figure 1E). The effect of A803647 was noticeable in both groups of animals, unsensitized (Figure 1C) and sensitized (Figure 1F), and for all the tested drug concentrations. The effect of A803467 was also similar to that of the control antitussive drug codeine.

3.1.2. Influence of Nav1.7 and Nav1.8 Blockers on sRaw Values

The value of sRaw was recorded for 2 min after the inhalation of each bronchoconstrictor (histamine and methacholine) (Figures 2 and 3). ProTx III exhibited an effect on the sRaw values only for the highest tested concentration (Figure 2A). Huwentoxin IV did not significantly influence the sRaw values (Figure 2B). Under physiological conditions, we recorded the following results: A803467 significantly reduced sRaw values, without a difference between the tested bronchoconstrictors (Figure 2C).

The pharmacodynamic effect of Nav1.7 as well as Nav1.8 blockers did not change during the development of inflammation (Figure 3). ProTx III (Figure 3A) significantly relieved the bronchoconstriction after histamine or metacholine inhalation but only at the highest concentration. Huwentoxin IV (Figure 3B) did not reduce the sRaw values after histamine or metacholine inhalation. A803467 reduced the sRaw values regardless of the bronchoconstrictor tested (Figure 3C) and, moreover, had an even more significant effect, according to some measurements, than the clinically used bronchodilator salbutamol.

3.1.3. Ciliary Beating Frequency Results

As expected (Figure 4), the CBF values were significantly increased in the group of animals that underwent ovalbumin sensitization.

Generally, TTX and Nav1.7 and Nav1.8 blockers modulated the CBF but had relatively little effect when tested under physiological conditions: TTX and ProTx III did not significantly influence ciliary beating, Huwentoxin IV significantly decreased the CBF only at the highest concentration used. The IC50 of the Nav1.8 blocker A803467 significantly inhibited the CBF, the main parameter determining mucociliary clearance; however, higher doses did not have a similar impact on cilia movements. Higher doses of A803467 increased the CBF but without statistical significance.
Under the OVA-induced inflammatory conditions, the CBF was significantly and dose-dependently suppressed by the non-selective Na\textsubscript{V} channel blocker TTX. Furthermore, the frequency of cilia movements was significantly reduced compared to that in the OVA− group. All the tested concentrations of ProTx III and A803467 as well as two higher concentrations of huwentoxin IV significantly decreased the CBF in the control group, which underwent sensitization by OVA, to the level of the CBF values in the healthy control group.

Figure 1. The number of cough efforts after administration of Nav 1.7 and Nav 1.8 blockers. N—measurement before any drug administration; 60 and 240—minutes after drug administration; (A)—ProTx III in physiological conditions; (B)—huwentoxin IV in physiological conditions; (C)—A803467 in physiological conditions; (D)—ProTx III in pathological conditions; (E)—huwentoxin IV in pathological conditions; (F)—A803467 in pathological conditions. P8—inhalation of ProTx III at concentration of 10\textsuperscript{−8} mols/L; P7—inhalation of 10\textsuperscript{−7} mols/L; P6—10\textsuperscript{−6} mols/L; H9—inhalation of huwentoxin IV at concentration of 10\textsuperscript{−9} mols/L; H8—10\textsuperscript{−8} mols/L; H7—10\textsuperscript{−7} mols/L; A8—inhalation of A803467 at concentration of 10\textsuperscript{−8} mols/L; A7—10\textsuperscript{−7} mols/L; A6—10\textsuperscript{−6} mols/L. Number of animals for each group: 7. Left column presents data obtained under physiological conditions. Right column presents data obtained after development of allergic inflammation. * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. OVA−; + p < 0.05 and +++ p < 0.001 vs. OVA+.
Figure 2. The changes in specific airway resistance values (sRaw) after administration of NaV1.7 and NaV1.8 blockers in physiological conditions. sRaw values are expressed as means ± S.E.M. N—measurement before drug administration; 60 and 240—minutes after drug administration; (A) of Figure 2—ProTx III; (B)—huwentoxin IV; (C)—A803467. For more detailed explanation, see the legend of Figure 1. * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. OVA−.
The changes in specific airway resistance values (sRaw) after administration of NaV1.7 and NaV1.8 blockers in allergic conditions. sRaw values are expressed as means ± S.E.M. sRaw values are expressed as averages ± SDs. N—measurement before drug administration; 60 and 240—minutes after drug administration; (A) of Figure 3—ProTx III; (B)—huwentoxin IV; (C)—A803467. For further detailed explanation, see legend of Figure 1. + p < 0.05, ++ p < 0.01 and +++ p < 0.001 vs. OVA+.
3.1.3. Ciliary Beating Frequency Results

As expected (Figure 4), the CBF values were significantly increased in the group of animals that underwent ovalbumin sensitization.

Figure 4. The values of ciliary beating frequency expressed in Hz, measured in unsensitized (OVA−) and sensitized (OVA+) animals after incubation of ciliated cells with individual concentrations of tested substances. P—ProTx III; H—huwentoxin IV; A—A803467. For a detailed explanation, see the legend of Figure 1. Left column presents data obtained under physiological conditions. Right column presents data obtained after development of allergic inflammation. *p < 0.05 and **p < 0.01 vs. OVA−; + p < 0.05, ++p < 0.01 and +++p < 0.001 vs. OVA+.

3.1.4. Changes in NaV1.7 and NaV1.8 Expression during Development of Inflammation

Based on the knowledge regarding the neuronal localization of TTX-sensitive and TTX-resistant NaV channels, we sought to determine whether the NaV1.7 and 1.8 subtypes were present in bronchial and lung tissue homogenates and if there were changes between the healthy group of animals and animals with allergic inflammation. This hypothesis was verified by the sandwich ELISA method. Isolated tissue of the respiratory tract (bronchial or pulmonary) was positive for NaV1.7 and NaV1.8 expression, unambiguously in favor of the NaV1.8 isoform, in both physiological and pathophysiological conditions (Figure 5). The expression of NaV1.8 in the bronchial homogenate of the healthy group was significantly lower than that in the group with ongoing chronic inflammation. These changes in lung tissue only narrowly exceeded statistical significance (Figure 5).
the differences between individual groups were not statistically significant. A803467 and ipratropium were more effective in cough suppression; however, the codeine. A803467 and ipratropium were more effective in cough suppression; however, the

Figure 5. Changes in expression of isoforms Nav1.7 and Nav1.8 before (OVA−) and after development of chronic allergic inflammation (OVA+). Number of animals for each group: 7; * p < 0.05 vs. OVA−.

3.1.5. Nav1.8 Blocker as Potential Asthma Reliever in Clinical Practice

Nav1.7 reduced the cough reflex and ciliary beating frequency but the physiological role, expression increase and constant effect on airway reactivity confirmed to us the decision to investigate only the effect of the Nav1.8 blocker in combination. Because of previously mentioned data and from the clinical practice point of view, we focused attention on the Nav1.8 blocker. We tested combinations of A803467 with salbutamol and ipratropium, clinically used relievers of asthma. We observed that such combinations affected the number of cough efforts, sRaw values and CBF.

Figure 6 presents the effects on AC-provoked coughing. Both combinations exhibited antitussive effects similar to A803467 itself, lower than those of the opioid antitussive codeine. A803467 and ipratropium were more effective in cough suppression; however, the differences between individual groups were not statistically significant.

The number of cough efforts after administration of A803467 with salbutamol/ipratropium combinations in pathological conditions. N—the number of coughs before drug administration; 60/240—minutes after drug administration; A—A803467 concentration of $10^{-8}$ mols/L; A + S—A803467 + salbutamol concentration of $4 \times 10^{-3}$ mols/L; A + I—A803467 + ipratropium concentration of $10^{-3}$ M/L. Number of animals for each group: 7; + p < 0.05 and +++ p < 0.001 vs. OVA+.

The effects of combinations on the sRaw were synergic (Figure 7). However, the Nav1.8 blocker alone significantly decreased the sRaw values regardless of the bronchoconstrictor used, but combinations with clinically used antiasthmatics intensified this
effect. Both combinations tested were significantly more effective in the suppression of histamine- and methacholine-induced airway constriction than the classic bronchodilatory drug salbutamol.

Figure 7. The changes in specific airway resistance values (sRaw) after the administration of the NaV1.8 blocker alone and with salbutamol/ipratropium in chronic inflammatory conditions. sRaw values are expressed as means ± S.E.M, and N means measurement before any drug administration; 60 and 240 are the minutes after the administration of a particular drug: A—A803467 concentration of $10^{-3}$ mols/L; A + S—A803467 + salbutamol concentration of $4 \times 10^{-3}$ mols/L; A + I—A803467 + ipratropium concentration of $10^{-3}$ mols/L. Number of animals for each group: 7; + $p < 0.05$, ++ $p < 0.01$ and +++ $p < 0.001$ vs. OVA+. # $p < 0.05$ vs. salbutamol.

The effects of salbutamol, ipratropium and their combinations with the NaV1.8 blocker on the CBF were also observed (Figure 8). Salbutamol had no impact on the ciliary frequency. The antimuscarinic drug ipratropium led to a decrease in this parameter, similar to A803467. However, their combination had a synergic effect on ciliary movement and further suppressed this parameter. On the other hand, the combination of A803467 and ipratropium decreased the CBF less than A803467 alone, and this decline was not statistically significant.

Figure 8. The values of ciliary beating frequency (Hz), measured in unsensitized (OVA−) and sensitized (OVA+) animals after the incubation of ciliated cells with A803467, classic bronchodilatory drugs and their combinations in OVA+ groups as follows: SAL—incubation with salbutamol concentration of $4 \times 10^{-3}$ mols/L; A8—A803467 at concentration of $10^{-8}$ mols/L alone; SAL + A8—A803467 with salbutamol; IPR—incubation with ipratropium at concentration of $10^{-3}$ mols/L; IPR + A—A803467 with ipratropium. * $p < 0.05$ vs. OVA−; + $p < 0.05$ and ++ $p < 0.01$ vs. OVA+. 
4. Discussion

In the present study, we proved the role of Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 in the modulation of airway defense reflexes in physiological conditions as well as during the development of allergic inflammation. Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 blockers seemed to be effective cough relievers regardless of whether the cough reflex was elicited under physiological conditions or by the chemical stimulation of inflamed airways. Furthermore, the Na\textsubscript{V}1.7 blocker A803467 significantly reduced the sRaw, highlighting its bronchodilatory effect. We also proved the role of Na\textsubscript{V} channels in the regulation of ciliary movement. The effect of Na\textsubscript{V}1.7 blockers on the CBF in physiological conditions, however, was minimal. By contrast, the lowest concentration of Na\textsubscript{V}1.8 tested significantly decreased the CBF. In pathological conditions, we proved the involvement of Na\textsubscript{V}1.7, especially in the TTX-mediated reduction of CBF, corresponding to the expression data. The obtained data significantly support the clinical use of the Na\textsubscript{V}1.8 blocker and its combination with clinically used antiasthmatics.

Coughing is the most important airway reflex that protects the airways and lungs from aspirated, inhaled irritants and accumulated secretions. Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 have been shown to be expressed in lung-specific vagal sensory neurons in human and animal models that display cough reflexes, e.g., guinea pigs [12], or on jugular and nodose ganglia [21]. These channels are upregulated in response to inflammatory mediators that are known to increase cough sensitivity [22]. Moreover, former and recent studies have already shown that cultured bronchial smooth muscle cells, including those from human airways, express Na\textsuperscript{+} currents [23]. Thus, sodium channels should be one of the several reasons for hyperreactivity, airway obstruction and pathological coughing.

The presence of Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 in homogenates from the tracheal and pulmonary tissue of healthy and OVA-sensitized guinea pigs was confirmed in this study. At the same time, we showed the involvement of Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 in the regulation of the cough reflex. Our experiments are consistent with numerous published findings [24,25]. Evans et al. [25] proved the involvement of Na\textsubscript{V}1.7 in the cough reflex, which explained benzonatate (a clinically used antitussive)'s mechanism of action in catecholamine A differentiated (CAD) cells, which express TTX-sensitive Na\textsubscript{V} channels, composed primarily of Na\textsubscript{V}1.7 with smaller contributions of Na\textsubscript{V}1.1 and Na\textsubscript{V}1.3. The selective inhibition of Na\textsubscript{V}1.7 via gene silencing in nodose sensory neurons reduces the excitability of these neurons and inhibits mechanically induced and citric-acid-induced coughing in guinea pigs [26]. Muroi and Undem [15] describe the upregulation of Na\textsubscript{V}1.8 expression and significantly reduced threshold for activation after the exposure of sensory neurons to an inflammatory mediator. Brozmanova et al., in 2019 [13], proved that the Na\textsubscript{V}1.8 inhibitor A803467 reduced capsaicin-induced coughing at doses that did not affect the respiratory rate. This could be achieved by either the systemic or local (inhalation) administration of the drug. However, the clinical relevance of such consistent results originated from various experimental studies is still limited. The main reason is controversial data from clinical trials. In clinical trials using nebulized lidocaine, about 50% of patients reported successful cough suppression but more than 40% reported some side effects including dysphonia, oropharyngeal numbness and a bitter taste [27]. Furthermore, the results for a novel selective blocker targeting Na\textsubscript{V}1.7 (GSK2339345) that was investigated in a randomized, double-blind, placebo-controlled crossover study in 16 patients with refractory chronic cough suggested no antitussive effect [28].

The exaggerated ASM contractile response characterizing bronchial hyperresponsiveness is the main pathophysiologic factor involved in the development of reversible airway obstruction, e.g., that seen in asthma [29]. Since the airway constriction in patients with asthma is believed to be mediated by the vagus nerve, blockers of Na\textsubscript{V} channels may be able to prevent airway constriction [30]. Na\textsubscript{V} modulators are discussed more as reliable tussigens or antitussives in the literature, but their ability to control airway smooth contractility is still not exactly clear. Although there have been published reports partially proving the ability of Na\textsubscript{V} channel blockers to reduce airway responsiveness to bronchoprovoking agents [31–33], each study has several limitations, e.g., the routes of Na\textsubscript{V} blocker...
administration, the low channel selectivity of the tested compounds or the low effective doses used. Unlike nodose and jugular ganglia or the neurons, where both channels were found to be expressed equally [7,21], our findings show dominant Na\textsubscript{V}1.8 expression in whole tissue homogenates. This highlights their potential extra-neuronal presence, e.g., on airway smooth muscle. The blockers of Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 tested in our study were administered in a localized manner, by inhalation at different concentrations that were selected in order to avoid activating another channels. The sRaw measurements show a dominant role of Na\textsubscript{V}1.8 in the regulation of the airway reactivity/hyperreactivity induced by histamine and methacholine. These findings also correspond with the results for the expression. However, a more important role of Na\textsubscript{V}1.7 in the control of parasympathetic airway contraction in humans and guinea pigs was previously suggested according to its expression in parasympathetic ganglia and the inhibitory effects of TTX and a Na\textsubscript{V}1.7 blocker on the contraction of isolated tracheal smooth muscle [31]. These differences could be explained by the different methods for testing airway reactivity. Moreover, this study was focused on the regulation of airway reactivity under physiological conditions only. In the OVA-sensitized guinea pigs, the blockade of Na\textsubscript{V}1.8 efficiently reduced the bronchoconstriction induced by mediators involved in the hyperreactivity associated with the chronic inflammation of the airways. The standard of care for treating mild to moderate asthma has remained largely unchanged for many years. The Global Initiative for Asthma (GINA) recommends a stepwise approach for the treatment of asthma. The preferred inhalation treatment options for persistent asthma varies depending on the severity, but at standard, includes inhaled glucocorticoids and bronchodilators, e.g., β\textsubscript{2}-agonists or anticholinergics [33]. One of the main problems in the management of asthmatic patients, regardless of the severity, type and therapeutic strategy chosen, is the limited duration of full therapeutic responses (due to the downregulation of β\textsubscript{2} receptors) or spectrum of side effects (anticholinergics). A Na\textsubscript{V}1.8 blocker was proved to be a compatible treatment in combinations with the β\textsubscript{2} agonist salbutamol and anticholinergic drug ipratropium. This combination not only resulted in sufficient control but also had a synergic effect in decreasing the sRaw, the main parameter determining airway hyperresponsiveness.

Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 are believed to be preferentially distributed in peripheral sensory neurons and the C-fibers of neurons innervating airways [11,12]. Inflammatory mediators (e.g., amines, prostanoids, kinins and nerve growth factor) can reduce the thresholds for the activation of these channels [34] or increase their expression in sensory neuronal cell bodies [17]. It corresponds with our experiments that were also focused on changes in the presence of Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 in inflamed airways. Despite the ELISA showing increased expression of both of the studied channel isoforms in the tracheal and lung tissue homogenates, only Na\textsubscript{V}1.8 was significantly overexpressed in tracheal tissue. However, Na\textsubscript{V}1.8 overexpression in the lungs can be partly associated with initial remodeling changes and the proliferation of vascular myocytes, where the presence of Na\textsubscript{V}1.8 has already been proved [10,11].

Mucociliary clearance ensures that the airways remain free of inhaled particles and detritus. A synchronous and fast ciliary beat, as well as the right amount and consistency of mucus, is essential for functioning mucociliary clearance. CBF is a key parameter controlling the rate of mucociliary clearance, and it is believed to be under vagal control [35]. The presence of Na\textsubscript{V}1.7 and Na\textsubscript{V}1.8 on afferent fibers of the vagal nerve points to their possible involvement in the control of ciliary movements. A regulatory role of Nav ion channels in the tracheal CBF has already been suggested [32]; however, the information about the role of Na\textsubscript{V} in ciliary beating remains limited. Our results significantly expand the knowledge related to the regulation of respiratory epithelium cilia motility. First, the incubation of ciliated epithelial cells with increased concentrations of the Na\textsubscript{V}1.8 blocker, which mimicked the inhalatory administration of the compound, lead to a statistically significant decrease in the CBF in samples from both healthy and OVA-sensitized airways. TTX and Na\textsubscript{V}1.7 blockers, tested under the same conditions, significantly reduced the CBF in OVA-sensitized animals. These findings confirm a role for Na\textsubscript{V}1.8 channels in the control
of cilia movements and point to a novel inflammation-induced regulatory role of Nav1.7 in CBF modulation. However, the TTX-induced inhibition of the CBF was, in fact, up to 40% greater. This could be explained by the possible involvement of other TTX-sensitive Nav channels in the regulation of airway cilia function. Ciliary ion channels are topics of active investigation. In the airways, cilia function in concert with airway mucus to mediate the critical function of mucociliary clearance, cleansing the airways of inhaled particles and pathogens. The treatment of respiratory diseases should not negatively affect the function of mucociliary clearance. The fact that the Nav1.8 blocker decreased ciliary beating in OVA-sensitized animals cannot be overlooked, despite the decline being to a level similar to physiological CBF. Significantly, the inhibitory effect of the Nav1.8 blocker was antagonized in combination with the β2 agonist salbutamol.

5. Conclusions
The presented work highlights new findings regarding Nav involvement in airway defense mechanisms. Blockers of Nav1.7 and Nav1.8 administered by inhalation exerted reliable suppressive effects on the cough reflex experimentally elicited under physiological conditions or by the chemical stimulation of inflamed airways. Nav1.7 seems to be more important in the cough reflex than in the process of airway smooth muscle contraction/relaxation. The changes in respiratory tract physiology induced by inflammatory mediators highlight the fact that Nav1.7’s involvement might be more important in chronic inflammatory disorders of the airways. Nav1.8 modulators maintained their effects in the regulation of airway defense mechanisms under physiological conditions as well as after the development of inflammation. The importance of the mentioned Nav subtype also confirms findings from the expression analysis confirming dominance in airway tissue presence and overexpression in bronchial homogenates after ovalbumin sensitization. Therefore, modulators of Nav channels could be regarded as future treatments for respiratory diseases associated with pathological coughing and/or airway hyperreactivity. Their impact on the regulation of mucociliary clearance, especially the CBF, cannot be overlooked. Nav1.8 showed compatibility with the asthma relievers used the most often in the clinic. Their additive effects on sRaw seem to be relevant from a clinical medicine point of view.

Author Contributions: Conceptualization, M.K. and M.S.; methodology, M.K. and J.B.; software, M.J.; validation, J.B., I.K. and M.S.; formal Analysis, M.J.; investigation, J.B.; resources, S.F.; data curation, J.B.; writing—original draft preparation, M.K.; writing—review and editing, M.S.; visualization, M.K. and M.S.; supervision, S.F.; project administration, S.F.; funding acquisition, M.S. and S.F. All authors have read and agreed to the published version of the manuscript.

Funding: This publication is the result of the project implementation VEGA 1/0253/19; VEGA 1/0314/21; APVV-19-0033; Biomedical Centre Martin, ITMS code: 2622020187, supported by the Operational Programme Research and Innovation funded by the ERDF; “Centre of Experimental and Clinical Respiriology II”, co-financed from EC sources, Measurement of Respiratory Epithelium Cilium Kinematics [262202219].

Institutional Review Board Statement: All the protocols described in the study were approved by the local Ethic Committee (IRB00005636 decision No. EK 40/2018) and followed the aims and objectives of the ARRIVE guidelines. The investigation followed the Guide for the Care and Use of Laboratory Animals: Eighth Edition (2010) published by the US Committee for the Update of the Guide for the Care and Use of Laboratory Animals; the National Research Council; the EU-adopted Directive 2010/63/EU of the European Parliament and of the council on the protection of animals used for experimental and other scientific purposes; and Slovak law regulating animal experiments.

Data Availability Statement: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to them containing information that could compromise the privacy of the research participants.

Acknowledgments: The authors want to thank Jesenska for technical support.

Conflicts of Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References

1. Widdicombe, J.G. Pulmonary and respiratory tract receptors. J. Exp. Biol. 1982, 100, 41–57. [CrossRef]
2. Kollarik, M.; Undem, B.J. Mechanisms of acid-induced activation of airway afferent nerve fibres in guinea-pig. J. Physiol. 2002, 543, 399–406. [CrossRef] [PubMed]
3. Undem, B.J.; Chuaychoo, B.; Lee, M.G.; Weinreich, D.; Myers, A.C.; Kollarik, M. Subtypes of vagal afferent C-fibres in guinea-pig lungs. J. Physiol. 2004, 556, 905–917. [CrossRef] [PubMed]
4. Kwong, K.; Carr, M.J.; Gibbard, A.; Savage, T.J.; Singh, K.; Jing, J.; Meeker, S.; Undem, B.J. Voltage-gated sodium channels in nociceptive versus non-nociceptive nodose vagal sensory neurons innervating guinea pig lungs. J. Physiol. 2008, 586, 1321–1336. [CrossRef]
5. Taylor-Clark, T.E.; Kollarik, M. Vague no more: Evidence of divergent central pathways of sensory nerves innervating the human airways. J. Physiol. 2020, 598, 5597–5598. [CrossRef]
6. Clairfeuille, T.; Xu, H.; Koth, C.M.; Payandeh, J. Voltage-gated sodium channels viewed through a structural biology lens. Curr. Opin. Struct. Biol. 2017, 45, 74–84. [CrossRef] [PubMed]
7. Sun, H.; Kollarik, M.; Undem, B.J. Blocking voltage-gated sodium channels as a strategy to suppress pathological cough. Pulm. Pharmacol. Ther. 2017, 47, 38–41. [CrossRef] [PubMed]
8. Carr, M.J. Regulation of cough and action potentials by voltage-gated Na channels. Pulm. Pharmacol. Ther. 2013, 26, 508–509. [CrossRef]
9. Dib-Hajj, S.D.; Binshokt, A.M.; Cummins, T.R.; Jarvis, M.F.; Samad, T.; Zimmermann, K. Voltage-gated sodium channels in pain states: Role in pathophysiology and target for treatment. Brain Res. Rev. 2009, 60, 65–83. [CrossRef]
10. Rice, F.L.; Albrecht, P.J.; Wymer, J.P.; Black, J.A.; Merkies, I.S.; Faber, C.G.; Waxman, S.G. Sodium channel Nav1.7 in vascular myocytes, endothelium, and innervating axons in human skin. Mol. Pain. 2015, 11, s12990-015. [CrossRef]
11. Jo, T.; Nagata, T.; Iida, H.; Imuta, H.; Iwasawa, K.; Ma, J.; Hara, K.; Omata, M.; Nagai, R.; Takaziwa, H.; et al. Voltage-gated sodium channel expressed in cultured human smooth muscle cells: Involvement of SCN9A. FEBS Lett. 2004, 567, 339–343. [CrossRef]
12. Kwong, K.; Carr, M.J. Voltage-gated sodium channels. Curr. Opin. Pharmacol. 2015, 22, 131–139. [CrossRef]
13. Brozmanova, M.; Svajdova, S.; Navelkova, N.; Muroi, Y.; Undem, B.J.; Kollarik, M. The voltage-gated sodium channel NaV1.8 blocker A-803467 inhibits cough in the guinea pig. Respir. Physiol. Neurobiol. 2019, 270, 103267. [CrossRef]
14. Renganathan, M.; Cummins, T.R.; Waxman, S.G. Contribution of Na(+)1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 2001, 86, 629–640. [CrossRef]
15. Muroi, Y.; Undem, B.J. Targeting Voltage Gated Sodium Channels NaV1.7, NaV1.8, and NaV1.9 for treatment of pathological cough. Lung 2014, 192, 15–20. [CrossRef]
16. Strickland, I.T.; Martindale, J.C.; Woodhams, P.L.; Reeve, A.J.; Chessell, I.P.; McQueen, D.S. Changes in the expression of NaV1.7, NaV1.8 and NaV1.9 in a distinct population of dorsal root ganglia innervating the rat knee joint in a model of chronic inflammatory joint pain. Eur. J. Pain 2008, 12, 564–572. [CrossRef]
17. Levinson, S.R.; Luo, S.; Henry, M.A. The role of sodium channels in chronic pain. Muscle Nerve 2012, 46, 155–165. [CrossRef]
18. Hall, I.P. Second messengers, ion channels and pharmacology of airway smooth muscle. Eur. Respir. J. 2001, 15, 1120–1127. [CrossRef]
19. Morice, A.H.; Fontana, G.A.; Belvisi, M.G.; Murrin, S.S.; Chung, P.V.; Dicpinigaitis, P.V.; Kastelik, J.A.; McGarvey, L.P.; Smith, J.A.; Tatar, M. ERS guidelines on the assessment of cough. Eur. Respir. J. 2014, 43, 1173–1181. [CrossRef]
20. Pennock, B.E.; Cox, C.P.; Rogers, R.M.; Cain, W.A.; Wells, J.H. A non-invasive technique for measurement of changes in specific airway resistance. J. Appl. Physiol. 1979, 46, 399–406. [CrossRef]
21. Sun, H.; Meeker, S.; Herbstomer, R.A.; Kollarik, M.; Undem, B.J. Differential Role of Nav Isoforms in the Induction vs Conduction of Action Potentials in Vagal Afferent Nerves. FASEB J. 2017, 31, 861–864. [CrossRef]
22. Brozmanova, M.; Pavelkova, N. The Prospect for Potent Sodium Voltage-Gated Channel Blockers to Relieve an Excessive Cough. Physiol. Res. 2020, 69, S7–S18. [CrossRef]
23. Sommer, B.; Flores-Soto, E.; Gonzalez-Avila, G. Cellular Na+ handling mechanisms involved in airway smooth muscle contraction. Int. J. Mol. Med. 2017, 40, 3–9. [CrossRef]
24. Muroi, Y.; Undem, B.J. Targeting peripheral afferent nerve terminals for cough and dyspnoe. Curr. Opin. Pharmacol. 2011, 11, 254–264. [CrossRef] [PubMed]
25. Evans, M.S.; Maglinger, G.B.; Fletcher, A.M.; Johnson, S.R. Benzonatate inhibition of voltage-gated sodium currents. Neuropsychopharmacology 2016, 41, 179–187. [CrossRef]
26. Mazzone, S.B.; McGarvey, L. Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough. Clin. Pharmacol. Ther. 2020, 109, 619–636. [CrossRef]
27. Available online: https://clinicaltrials.gov/ct2/show/NCT04000633 (accessed on 27 June 2019).
28. Roe, N.A.; Lundy, F.T.; Litherland, G.J.; McGarvey, L.P.A. Therapeutic Targets for the Treatment of Chronic Cough. Curr. Otolorhinolaryngol. Rep. 2019, 7, 116–128. [CrossRef]
29. Pelaia, G.; Renda, T.; Gallelli, L.; Vatrella, A.; Busceti, M.T.; Agati, S.; Caputi, M.; Cazzola, M.; Maselli, R.; Marsico, S.A. Molecular mechanisms underlying airway smooth muscle contraction and proliferation: Implications for asthma. Respir. Med. 2008, 102, 1173–1181. [CrossRef]
30. Muraki, M.; Iwanaga, T.; Haraguchi, R.; Kubo, H.; Tohda, Y. Continued inhalation of lidocaine suppresses antigen-induced airway hyperreactivity and airway inflammation in ovalbumin-sensitized guinea pigs. *Int. Immunopharmacol.* 2008, 8, 725–731. [CrossRef] [PubMed]

31. Kocmalova, M.; Kollarik, M.; Canning, B.J.; Ru, F.; Herbstromer, R.A.; Meeker, S.; Fonquerna, S.; Aparici, M.; Miralpeix, M.; Chi, X.; et al. Control of Neurotransmission by NaV1.7 in Human, Guinea pig, and Mouse airway Parasympathetic Nerves. *J. Pharmacol. Exp. Ther.* 2017, 361, 172–180. [CrossRef] [PubMed]

32. Kocmalova, M.; Joskova, M.; Franova, S.; Banovcin, P.; Sutovska, M. Airway defense control mediated via voltage-gated sodium channels. *Adv. Exp. Med. Biol.* 2016, 921, 71–80. [PubMed]

33. Mavissakalian, M.; Brady, S. The Current State of Biologic Therapies for Treatment of Refractory Asthma. *Clin. Rev. Allergy Immunol.* 2020, 59, 195–207. [CrossRef] [PubMed]

34. Amaya, F.; Wang, H.; Costigan, H.; Allchorne, A.J.; Hatcher, J.P.; Egerton, J.; Stean, T.; Morisset, V.; Grose, D.; Gunthorpe, M.J.; et al. The voltage-gated sodium channel Na(v)1.9 is an effector of peripheral inflammatory pain hypersensitivity. *J. Neurosci.* 2006, 26, 12852–12860. [CrossRef] [PubMed]

35. Eljamal, M.; Wong, L.B.; Yeates, D.B. Capsaicin-activated bronchial- and alveolar-initiated pathways regulating tracheal ciliary beat frequency. *J. Appl. Physiol.* 1994, 77, 1239–1245. [CrossRef] [PubMed]